



## PHARMACEUTICAL 2018











## PHARMACEUTICAL 2018



## Aeglea BioTherapeutics Inc. Rank 71 of 342



The relative strengths and weaknesses of Aeglea BioTherapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aeglea BioTherapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 94% points. The greatest weakness of Aeglea BioTherapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 32% points.

The company's Economic Capital Ratio, given in the ranking table, is 192%, being 146% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	54,991
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,629
Liabilities, Non-Current	111
Other Assets	232
Other Compr. Net Income	-98
Other Expenses	0
Other Liabilities	0
Other Net Income	5,645
Other Revenues	0
Property and Equipment	854
Research and Development	22,815
Selling, General and Administrative Expense	10,066

Output Variable	Value in 1000 USD
Assets	56,077
Liabilities	5,740
Expenses	32,881
Revenues	0
Stockholders Equity	50,337
Net Income	-27,236
Comprehensive Net Income	-27,285
Economic Capital Ratio	192%

